InstalabLoading...
InstalabLoading...
About 1 in 100 people have celiac disease, yet most go undiagnosed for years. The standard screening blood test, called tTG IgA (tissue transglutaminase IgA), is excellent for most adults, but it has blind spots. It can miss celiac disease in young children under two, in anyone with low IgA (a common immune protein), and in some adults whose results fall in a gray zone. DGP IgG exists to fill those gaps.
DGP IgG (deamidated gliadin peptide IgG) measures a specific type of antibody your immune system produces when it reacts to gluten. Unlike older "gliadin" tests that were imprecise and have been retired, this second-generation test targets a chemically modified form of gluten that your body creates during the disease process itself. That makes it far more accurate, and in certain populations, it catches cases that the primary screening test cannot.
When you eat gluten, your gut breaks it into smaller protein fragments called gliadin peptides. In people with celiac disease, an enzyme in the intestinal lining called tissue transglutaminase (often shortened to tTG or TG2) chemically modifies these fragments through a process called deamidation. The modified fragments are much more visible to the immune system. Your immune cells recognize them as threats and produce antibodies against them.
DGP IgG is one of those antibodies. It belongs to the IgG class, meaning it circulates in your blood regardless of your IgA levels. This is why DGP IgG remains detectable even in people who produce little or no IgA, a situation where the standard tTG IgA test gives falsely reassuring results. A rising DGP IgG level signals that your immune system is actively reacting to gluten in a way that typically accompanies intestinal damage.
The primary screening test for celiac disease is tTG IgA, and for most people over age two with normal IgA levels, it works well. DGP IgG becomes valuable in three specific situations where tTG IgA falls short.
If you do not fall into one of these categories, tTG IgA alone is usually sufficient. In a large pediatric cohort of 3,555 children, adding DGP testing to tTG IgA would have identified only 0.18% additional celiac cases. The test adds the most when the standard approach has a known limitation.
One of the most interesting findings about DGP IgG comes from prospective studies that follow children with a family history of celiac disease. In a cohort of 325 at-risk children, a rise in DGP IgG preceded the rise in tTG IgA (the standard marker) by roughly 6 to 12 months. About 74% of children who eventually developed celiac disease showed elevated DGP IgG before tTG IgA turned positive.
This suggests DGP IgG can serve as an early signal that a child's immune system is losing tolerance to gluten, before the full autoimmune response to tTG kicks in. For families with a known celiac history, tracking DGP IgG alongside tTG IgA could shorten the diagnostic delay. However, an elevated DGP IgG without a concurrent rise in tTG IgA is not, by itself, a diagnosis. It is a signal that warrants closer monitoring, not immediate lifelong dietary restriction.
Once celiac disease is diagnosed, the treatment is a strict gluten-free diet. DGP IgG levels typically fall as gluten is removed and intestinal healing occurs. In a study of 119 pediatric celiac cases, all antibody levels (including DGP) declined after six months on a gluten-free diet. Deamidated gliadin antibodies also correlate with the degree of villous atrophy (damage to the finger-like projections lining the small intestine), making them a useful, though imperfect, window into mucosal health.
That said, serology alone is not a reliable proof of perfect diet adherence. A multicenter study of 188 celiac patients on a gluten-free diet found that nearly 30% had detectable gluten fragments in their stool, yet 83% of those with the highest gluten exposure still tested negative on DGP IgA. Small or intermittent gluten exposures may not trigger a measurable antibody rise. If your DGP IgG normalizes, it is encouraging but not a guarantee that your gut has fully healed or that trace gluten is not getting through.
DGP IgG is interpreted as a positive or negative result, not as a continuous scale with "optimal" zones. The cutpoint that separates positive from negative depends entirely on the assay your lab uses. There is no single universal threshold.
These ranges come from commonly used commercial assays (primarily INOVA/Quanta Lite platforms) studied in clinical cohorts. They are illustrative orientation for understanding your result, not a substitute for your own lab's reported reference interval.
| Result | Typical Threshold | What It Suggests |
|---|---|---|
| Negative | Below lab cutpoint (e.g., <20 kU/L or <19 units) | No significant immune reaction to deamidated gluten detected at this time |
| Positive | At or above lab cutpoint (e.g., ≥20 kU/L or ≥19 units) | Active immune response to gluten; celiac disease should be investigated with additional testing and possibly biopsy |
Compare your results within the same lab over time for the most meaningful trend. Different assay manufacturers use different units, scales, and cutoffs, so a number from one lab cannot be directly compared to a number from another.
Because DGP IgG measures an immune response to gluten, the most common source of a misleading result is gluten avoidance. If you have already started reducing or eliminating gluten before being tested, your DGP IgG may be falsely low or negative, even if you have active celiac disease. For an accurate initial diagnostic test, you need to be eating gluten regularly.
No published data exist on whether common medications (statins, metformin, corticosteroids, proton pump inhibitors) or acute events (illness, surgery, intense exercise) significantly affect DGP IgG levels. This is a gap in the literature, not evidence that these factors are irrelevant. If you are taking immunosuppressive medications, mention this when interpreting results with a clinician, as any treatment that broadly suppresses antibody production could theoretically lower autoantibody titers.
A single DGP IgG result tells you whether your immune system is reacting to gluten right now. Serial measurements tell you a much richer story: whether your gluten-free diet is working, whether your intestinal immune response is quieting down, and whether a previously borderline result is trending toward or away from positivity.
If you have been diagnosed with celiac disease, retest DGP IgG (along with tTG IgA if applicable) roughly 6 months after starting a strict gluten-free diet, then annually. A declining trend confirms that the dietary change is reducing the immune response. Persistent positivity after 12 months of strict avoidance warrants investigation for hidden gluten sources or a possible complication like refractory celiac disease.
If you are testing proactively because of a family history of celiac disease, get a baseline while you are still eating gluten. If the result is negative, retest every one to two years, because celiac disease can develop at any age. If you notice a rising trend, even within the "negative" range, that trajectory may be more informative than any single number.
A positive DGP IgG does not, by itself, diagnose celiac disease. It is one piece of a diagnostic puzzle. The next steps depend on your full clinical picture.
For anyone with a positive result and no prior diagnosis, consultation with a gastroenterologist is the clearest path forward. Do not start a gluten-free diet before completing the diagnostic workup, because removing gluten will lower antibody levels and make subsequent testing and biopsy harder to interpret.
Evidence-backed interventions that affect your DGP IgG level
DGP IgG is best interpreted alongside these tests.